Skip to content
Screener

Novavax NVAX Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$56.7MBeat by $4.2M
EPS-$0.32Beat by $0.06
Revenue estimate$52.5M
EPS estimate-$0.38

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$72.7M
EPS estimate-$0.37

Financials

Q2 2026

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.52B+13.2%
Enterprise value$1.63B+41.2%
P/S3.7×+2.4×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp

Returns & leverage

See full
Current ratio2.3×0.0×

Segments

By product

See full
Licensing, royalties, and other$37.8M-83.4%
Cost reimbursements$22.6M+249%
Upfront fee amortization$8.7M-28.9%
Milestones amortization$3.8M-33.6%
Royalties$700.0K-86.0%

By geography

See full
Rest of the world$17.1M-54.2%
Europe$1.1M-69.2%

By segment

See full
Reportable Segment$56.7M-76.3%

FAQ

When did Novavax report Q2 2026 earnings?
Novavax (NVAX) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Novavax's Q2 2026 revenue and EPS?
Novavax reported revenue of $56.7M and eps of $-0.32 for Q2 2026.
Did Novavax beat estimates in Q2 2026?
Revenue beat the consensus estimate of $52.5M by $4.2M. EPS beat the consensus estimate of $-0.38 by $0.06.
How did Novavax's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 76.3% from $239.2M a year earlier.
Where can I find Novavax's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001000694-26-000019) and the 10-Q periodic report (0001000694-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.